Hims & Hers isn't worth owning because of its management: a leader who can pump and then dump the stock is not a trustworthy type. Zeta Global is the preferable alternative. x.com 

Hims & Hers suffers from bad management, and government pressure is squeezing its pharma margins. x.com 

Hims & Hers has enormous long-term potential from its brand, personalized platform and recurring model, and that upside heavily outweighs the bear case. Regulation and customer retention are real questions, and they explain why the opportunity exists. x.com 

Hims & Hers is going through a major transition period with no growth, so it is not worth owning right now, even though the long-term view remains bullish. x.com 

Hims & Hers is not a $100 stock yet, because growth is slowing and there is no new driver on the scale of GLP-1. Customer acquisition and conversion are slowing and average spend per user is declining, which quarter-over-quarter figures show better than the 40%+ year-over-year narrative. Guidance was narrowed and comparisons get harder. Investing on past strong growth is looking backward. Hims is a great company, but the stock will take time to reach new highs. x.com 

Hims & Hers' peptide capabilities may be underappreciated, setting up a strong bounce after peptide news. Per @riyadosofian, it is the only telehealth company with a peptide facility and global distribution system. A strong bounce is expected now as the stock holds outside its wedge. x.com  x.com 

Hims & Hers looks good on paper, but past revenue growth does not guarantee future growth and margins are falling, which is very bad. Its peptides story could rerate the stock if executed, but it brings another regulatory overhang: peptides will be in regulation headlines every day and the stock will trade on them. x.com 

Hims & Hers is a meme stock, not a fundamental story, after missing EPS by 1,440%, with earnings down 300% year over year and 600% quarter over quarter. The company pays influencers to pump the stock, and even a move to $200 would not change that view. x.com  x.com 

Hims & Hers looks bullish after its first open-market insider buy in years, because insiders sell for various reasons but buy for only one. Per @himshouse, director David B. Wells, formerly Netflix's CFO, bought 48.4k shares for $1.2 million. A monthly close above $25 is all Hims & Hers needs. x.com 

Hims & Hers' latest earnings show a deteriorating business, and hype is not worth much when that happens. x.com  x.com